Business Overview: Heart Test Laboratories, Inc. (NASDAQ: HSCS)

---

Executive Summary

Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company applying artificial intelligence to the standard electrocardiogram (ECG/EKG) to detect a wider range of heart conditions — particularly early markers of cardiac dysfunction that conventional ECG analysis misses. Its fiscal year ends April 30.

HeartSciences matters because it is targeting a genuinely massive, already-existing testing volume (1.5-3.0 million ECGs performed worldwide daily, over 100 million per year in the U.S.) with an AI overlay rather than asking providers to adopt an entirely new diagnostic modality — though as of its most recent 10-K, its core products are not yet FDA-cleared.

---

1. Core Business Model & How They Work

HeartSciences plans to sell its MyoVista ECG hardware under a razor/razor-blade model, generating recurring revenue from proprietary electrodes, and plans a separate cloud-platform/algorithm subscription business once regulatory clearances are obtained.

[ MyoVista wavECG Device (Hardware) ] ➡️ [ Recurring Proprietary Electrode Sales ] ➡️ [ MyoVista Insights Cloud Platform ] ➡️ [ Algorithm Subscription/Usage Fees (Future) ]

Key operational drivers:

1. Dual-pathway regulatory strategy — the core MyoVista wavECG device (Class II) is pursuing 510(k) clearance (targeted Q1 2025 submission, having shifted from an earlier De Novo pathway), while a separate cloud platform and low-ejection-fraction algorithm target mid-2025 FDA submission.
2. Razor/razor-blade economics — device sales are a one-time transaction, but proprietary electrodes needed for each test create a recurring consumables revenue stream.
3. Device-agnostic cloud platform — the MyoVista Insights Cloud Platform is designed to host AI-ECG algorithms (internal or third-party) usable with existing ECG machines already in the field, not just HeartSciences' own hardware.
4. Licensed algorithm pipeline — the first planned cloud algorithm, detecting low ejection fraction (LVEF ≤40), is licensed from Mount Sinai under a September 2023 agreement, supplementing internally developed AI-ECG capability.

---

2. Business Segments

HeartSciences operates as a single, pre-commercial medical device business; it does not report formal segments. Its activities split conceptually between the MyoVista hardware/electrode line and the still-earlier-stage cloud/algorithm platform.

---

3. Product Portfolio

---

4. Competitive Landscape

Traditional ECG manufacturers: GE Healthcare Technologies, Koninklijke Philips N.V., Baxter International, and Nihon Kohden Corporation — large, established medical device companies that dominate the installed base of ECG machines HeartSciences' cloud platform would need to interoperate with (or compete against directly on hardware).

AI-ECG and AI-healthcare entrants: Anumana, Inc., Tempus Labs, Inc., and VIZ.ai — newer, well-funded competitors applying AI specifically to ECG or broader healthcare diagnostics, representing the more direct competitive threat to HeartSciences' core value proposition.

---

5. Strategic Strengths & Risks

Strengths

• Targets an enormous existing testing base (100+ million U.S. ECGs annually) rather than needing to create new testing behavior from scratch.
• Device-agnostic cloud platform strategy, if successful, could let HeartSciences monetize AI algorithms across a far larger installed base of ECG machines than its own hardware alone.
• A CPT Category III code already exists for AI-assisted ECG risk assessment of cardiac dysfunction, providing an early reimbursement pathway framework.
• Mount Sinai licensing relationship brings external clinical credibility and algorithm development to supplement internal R&D.

Risks

• Not yet FDA-cleared — as of the FY2024 10-K, none of HeartSciences' MyoVista products or AI-ECG algorithms are cleared for marketing, meaning the company currently has no approved product generating revenue from its core technology.
• Competing against both entrenched, well-capitalized traditional ECG manufacturers (GE, Philips, Baxter, Nihon Kohden) and well-funded AI-healthcare entrants (Tempus, Anumana, VIZ.ai) on two fronts simultaneously.
• CPT Category III codes are temporary and do not guarantee permanent reimbursement coverage — the company itself acknowledges this uncertainty.
• Its CE Mark (EU) lapsed in February 2022 under the old directive, and it has not yet obtained an EU MDR certificate, limiting near-term international commercialization.
• Small scale — only 15 full-time employees and 6 independent contractors as of mid-2024, a fraction of the resources available to its named large competitors.

---

6. Financial Overview

---

7. Summary Conclusion

HeartSciences is pursuing a genuinely large addressable opportunity — overlaying AI onto the ECG, one of medicine's highest-volume, lowest-cost diagnostic tests — with a razor/razor-blade hardware model and a device-agnostic cloud platform that could in principle extend beyond its own installed base. The company's patent estate and Mount Sinai licensing relationship provide some real differentiation. But as of its most recent 10-K, HeartSciences has no FDA-cleared product and generates no material commercial revenue from its core technology, and it must compete against both entrenched ECG hardware giants and well-funded AI-healthcare entrants once it does clear regulatory hurdles. The company's near-term trajectory hinges almost entirely on successfully navigating its 510(k) submission and subsequent FDA review.